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Abstract The interaction of the adrenoleukodystrophy protein
(ALDP), mutated in the peroxisomal disorder X-linked adreno-
leukodystrophy, and the very long-chain acyl-CoA synthetase
(VLACS), the enzyme whose function is missing in this disease,
remains obscure. As a first step to studying this interaction in
wild type versus ALDP-deficient mice, we have cloned a VLACS
cDNA from mouse liver. The 1860 bp open reading frame
encodes a 620 amino acid protein with a predicted molecular
mass of 70.3 kDa. By Northern blot analysis, a 2.6 kbp VLACS
mRNA was highly abundant in liver and kidney and present at
low levels in brain and testes. By RT-PCR VLACS mRNA was
also detected in heart and lung but remained undetectable in
skeletal muscle and spleen. In contrast to the peroxisomal L-
oxidation marker acyl-CoA oxidase, whose mRNA level steadily
increases during brain development, the VLACS transcript was
found at a constant low level from embryo through adulthood,
suggesting that additional isoforms may exist in brain.
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1. Introduction
The principal biochemical abnormality of X-linked adreno-
leukodystrophy (ALD) is the accumulation of saturated and
unbranched very long-chain fatty acids (VLCFA; sC22) in
nervous system white matter, adrenal cortex, and other tis-
sues, as well as in plasma and red blood cells [1]. This is
due to de¢cient activation of VLCFAs, i.e. coupling of coen-
zyme A to the fatty acid, necessary for entering the peroxiso-
mal L-oxidation pathway [2^5]. The enzyme responsible for
VLCFA activation, very long-chain acyl-CoA synthetase
(VLACS; also termed VLCFA-CoA ligase), has been de-
scribed as a peroxisomal transmembrane protein with the ac-
tive site either on the luminal [6] or the cytoplasmic [7] surface
of the peroxisomal membrane. A VLACS cDNA was recently
cloned from rat liver [8]. The predicted amino acid sequence
of VLACS showed high sequence similarity to fatty acid
transport protein, but was distinctly di¡erent from the long-
chain acyl-CoA synthetase. However, the VLACS gene seems
to be una¡ected in X-ALD patients, as the strategy of posi-
tional cloning disclosed inherited defects in another gene, the
ald gene, which is located on the X chromosome (Xq28) and
encodes a di¡erent peroxisomal membrane protein [9,10].
More than 120 ald mutations have been detected in ALD
patients so far (reviewed in [11]). Transfection of cultured
¢broblasts from ALD patients with cDNA encoding the
ALD protein (ALDP) can correct the de¢cient VLCFA me-
tabolism in these cells [12,13]. ALDP-de¢cient cells are also
capable of L-oxidation when already activated VLCFA are
used as substrate [2], suggesting that an interaction between
ALDP and VLACS is essential. However, neither the mecha-
nism of interaction, e.g. ALDP as a transporter of or anchor
for VLCFA-CoA synthetase in the peroxisomal membrane
[14], nor the pathobiochemical role of ALDP in adrenoleuko-
dystrophy has been clari¢ed. Several groups have recently
generated ALDP-de¢cient mice, which mirror the biochemical
defect of human ALD [15^17]. In order to compare the status
of VLACS in wild type and ALDP-de¢cient mice, we have
now cloned and characterized the mouse VLACS cDNA.
Here we describe the normal tissue distribution of the VLACS
mRNA and, while the nervous system is the most severely
a¡ected site in adrenoleukodystrophy, we also compared the
developmental time course of VLACS mRNA expression in
the brain to the expression pro¢les of the ALD mRNA and
the acyl-CoA oxidase mRNA, a marker for peroxisomal L-
oxidation.
2. Materials and methods
2.1. Cloning of mouse VLACS cDNA
We searched the dbEST (non-redundant database of GenBank
+ EMBL-DDBJ EST Division [18]) with the rat VLACS cDNA se-
quence (dbj D85100) and identi¢ed several mouse expressed sequence
tag (EST) clones. EST clones AA537712 and AA275019 were used for
the design of a mouse-speci¢c upstream PCR primer (Oli. 178: 5P-
GCCGCCGCGCTGCACGCCTCG-3P) and downstream PCR primer
(Oli. 180: 5P-GTCTATCGAGTTTCTTTCTGG-3P), respectively (po-
sitions 725^746 and 2680^2701 of the rat cDNA [8]). Poly(A)
mRNA was extracted from adult BALB/c mouse liver using Dyna-
beads Oligo (dT)25 (DYNAL), according to the manufacturer’s in-
structions, reverse transcribed using random hexamer primers and
PCR ampli¢ed on a thermal cycler (Perkin Elmer, GeneAmp 2400)
by 32 cycles of PCR (10 s at 94‡C, 30 s at 59‡C, and 4 min at 72‡C)
using 25 pmol of each primer and 2.5 units of Taq DNA polymerase
(Advanced Biotechnologies). The PCR products were cloned into
pCR II (Invitrogen) and sequenced. Mouse liver adaptor-ligated
cDNA (Marathon PCR-Ready cDNA, Clontech) was used as a tem-
plate in nested PCR reactions. The PCR product resulting from Oli.
205 (5P-CCAGTTACGCGAGGCCTCGGTTCCTGAG-3P) and
adaptor primer AP1 (Clontech) was boosted in a 1:100 dilution
with primers Oli. 190 (5P-ATTGATAAAACTCTGAAGCTC-3P)
and AP2 (Clontech). The PCR products were cloned into pCR 2.1
(Invitrogen) and sequenced mainly on an automated £uorescence se-
quencing device (ABI-373A Sequencer) using £uorescent dye dideoxy
terminator sequencing chemistry (ABI) according to the manufactur-
er’s recommendations. The VLACS cDNA sequence has been depos-
ited in the EMBL database (accession number AJ223958).
2.2. Northern blot analysis
Fresh mouse tissues or embryos (C57BL/6 or hybrid strains back-
crossed to C57BL/6) were dissected, and total cellular RNA was iso-
lated from frozen material as previously described [19]. For Northern
blot analyses 10 Wg aliquots of total RNA or 1^2 Wg of poly(A)
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RNA (oligo-dT-selected fraction from 100 Wg total RNA samples),
and a size marker (RNA ladder, BRL) were fractionated on 1.2%
agarose-formaldehyde gels [20] and transferred to nitrocellulose mem-
branes (Schleicher and Schuell). As a control of equal loading and
transfer, all blots were probed with a mouse cDNA [21] of the ubiq-
uitously expressed cyclophilin mRNA [22]. A 543 bp VLACS cDNA
fragment (mapping position 370 to 473 of the mouse cDNA sequence
in Fig. 1) was used for detection of the VLACS mRNA, after radio-
active labelling by random priming using [K-32P]dCTP (Amersham).
For detection of the acyl-CoA oxidase mRNA, a cDNA probe cor-
responding to nucleotides 174^1834 of the mouse peroxisomal acyl-
CoA oxidase mRNA (GenBank accession number AF006688) was
kindly provided by C.H. Noehammer (University of Graz, Austria).
All blots were washed to high stringency (68‡C, 0.2USSC/0.2% SDS)
before autoradiographic exposure to X-OMAT AR (Kodak) ¢lm and
intensifying screens.
2.3. RT-PCR analysis
Approximately 2 Wg of total cellular RNA (extracted as described in
Section 2.2) was reverse transcribed and PCR ampli¢ed using the
Titan One Tube RT-PCR System (Boehringer Mannheim) with Oli.
205 and Oli. 180 (sequences listed above). This primer combination
was selected such that a 261 bp VLACS-speci¢c product is ampli¢ed
from cDNA, but an intron in the VLACS gene (J. Berger, unpub-
lished data) discriminates products arising from genomic DNA poten-
tially contaminating the RNA extracts. RT-PCR was performed
under conditions not allowing quantitative analysis. As a positive
control, RT-PCR of an ALD-speci¢c fragment of similar size (which
should be obtained from all tissues) was performed on the same RNA
preparations.
3. Results
3.1. Cloning of mouse VLACS cDNA
Using a PCR-based approach, we have cloned and deter-
mined the sequence of a 2220 bp cDNA containing the com-
plete coding region of a putative VLACS from mouse liver.
Nucleotide sequence analysis (Fig. 1) revealed an open read-
ing frame of 1860 bp encoding a 620 amino acid protein with
a predicted molecular mass of 70.3 kDa. This protein can be
aligned without gaps to rat liver VLACS [8] and a human
liver VLACS sequence (dbj data base accession number
D88308), displaying 93% and 82% amino acid identity, respec-
tively (Fig. 2). Most of the amino acid substitutions are con-
servative, leaving no doubt that the mouse sequence repre-
sents an ortholog of the rat liver synthetase. Two
polyadenylation signals are indicated in the sequence (under-
lined in Fig. 1), and cDNA clones originating from mRNAs
polyadenylated at either one of these were obtained, demon-
strating that both sites are used in vivo.
3.2. Tissue distribution of mouse VLACS mRNA
The size tissue distribution of the VLACS mRNA was an-
alyzed by Northern blot hybridization, using total cellular
RNA (Fig. 3) or poly(A) RNA (Fig. 4). A VLACS
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Fig. 1. cDNA and deduced amino acid sequence of the mouse VLACS. The A of the translation initiation codon is number 1. Two utilized
polyadenylation signals are underlined.
6
Fig. 2. Alignment of the amino acid sequences of the mouse, rat, and human ortholog VLACS proteins. Standard one-letter amino acid sym-
bols are used. Dots represent identical amino acids at the apropriate position.
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mRNA of 2.6 kbp was expressed at high levels in samples
from liver and kidney, and at low levels in brain and testes.
The cloned cDNA was slightly shorter than the estimated 2.6
kbp mRNA size; adding an average size poly(A) tail still
leaves 100^200 nucleotides unaccounted for. Preliminary
data suggest that this is also the extent of missing 5P untrans-
lated sequence. In testes an additional, smaller (2.0 kbp),
slightly more abundant transcript was present. However, in
this tissue additional transcripts without functional relevance
are often seen. Heart, skeletal muscle, spleen, and lung re-
vealed no VLACS mRNA at the level of sensitivity of our
Northern blot analysis. However, by reverse transcription-
coupled PCR (a more sensitive assay), PCR products indica-
tive of VLACS mRNA expression (see Section 2) were ob-
tained from heart and lung, in addition to the sites of expres-
sion detected by Northern blot. In skeletal muscle and spleen
VLACS expression remained undetectable.
To evaluate the possibility of a coordinated temporal reg-
ulation of the ALD and VLACS genes during mouse brain
di¡erentiation, the developmental time course of VLACS
mRNA expression was investigated. By Northern blot hybrid-
ization, the 2.6 kbp VLACS transcript was found in the CNS
at a constant, low level from the earliest time point (embry-
onic day 12) through adulthood (Fig. 4). This is in contrast to
the ALD mRNA, whose expression is the highest in the im-
mature mouse brain and gradually decreases during di¡eren-
tiation (Berger et al., manuscript in preparation). Since the
exact role of the ALD protein in L-oxidation has not been
established, we also investigated the mRNA expression pro¢le
of mouse peroxisomal acyl-CoA-oxidase (ACOX), the ¢rst
enzyme of the peroxisomal L-oxidation system (Fig. 4). The
ACOX mRNA was relatively abundant in all tissues analyzed,
with the highest levels in liver and kidney. During brain de-
velopment the ACOX mRNA was easily detected at embry-
onic day 12 (at least 30-fold more abundant than VLACS)
and the expression steadily increased to the adult level, which
was estimated to be about 100-fold higher than the VLACS
level.
4. Discussion
We have cloned and sequenced a cDNA of the mouse
VLACS. Protein alignments demonstrate 93% amino acid
identity to rat liver VLACS [8], for which also VLCFA-
CoA synthetase activity and a peroxisomal and microsomal
subcellular localization were demonstrated. The amino acid
sequences of both species lack consensus motifs corresponding
to known peroxisomal targeting signals [23,24], as is the case
for ALDP and a number of other peroxisomal membrane
proteins including all peroxisomal half-ABC transporters, sug-
gesting that a di¡erent targeting mechanism operates on this
group of peroxisomal proteins. Although VLACS is thought
to be a peroxisomal membrane protein [6,7], hydropathy anal-
ysis [25] indicated no extensive hydrophobic domains other
than the amino-terminus, unlike peroxisomal membrane pro-
tein 70 kDa and 69 kDa [26^28], adrenoleukodystrophy pro-
tein [9] and adrenoleukodystrophy related protein [29], which
all have six transmembrane regions.
A strong expression of VLACS mRNA was observed in
liver and kidney, in good agreement with the overall high level
of L-oxidation in these tissues and the distribution of the rat
VLACS mRNA [8]. In addition, the mouse mRNA was found
at a much lower abundance, but still detectable by Northern
blot analysis, in testes and brain, which was not reported in
the rat VLACS study [8], possibly due to di¡erences in the
sensitivity of detection. Only by RT-PCR were VLACS tran-
scripts detectable also in heart and lung.
Brain contains quite high amounts of VLCFAs, such as
lignoceric acid [30]. VLACS activity, as well as acyl-CoA oxi-
dase activity, was shown to be present in peroxisomes and
microsomes of postnatal brain homogenates from 1^6 week
old rats, with a maximum around day 10^16 [31]. Further-
more, VLACS activity was also demonstrated within the mye-
lin membrane [32]. Thus, the low level of VLACS mRNA
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Fig. 3. Northern blot analysis of VLACS mRNA expression in vari-
ous mouse tissues. Total RNA (10 Wg per lane) from kidney (K),
heart (H), skeletal muscle (M), spleen (SP), testes (Tes), lung (Lu),
brain (B), and liver (L) of a 2 month old male was hybridized with
32P-labeled cDNA probes. Top panel: VLACS; bottom panel: cy-
clophilin (Cyph). The positions of RNA size standards are indicated
on the right.
Fig. 4. Northern blot analysis of VLACS mRNA distribution dur-
ing brain development and in adult tissues. Poly(A) RNA (1^2 Wg
per lane) was extracted from dissected brain or whole head (lanes
E12 and E14) at the indicated developmental stages and hybridized
with 32P-labeled cDNA probes. Top panel: VLACS; middle panel:
acyl-CoA oxidase (ACOX); bottom panel: cyclophilin (Cyph) as
loading control. The positions of RNA size standards are indicated
on the right. The lanes are labeled: E12^E18, 12.5^18.5 days of ges-
tation; P2^P30, days of postnatal development; adult brain (Ad),
liver (L), kidney (K), and testes (Tes).
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expression in mouse brain and the lack of upregulation during
postnatal di¡erentiation were unexpected. The acyl-CoA oxi-
dase mRNA, in contrast, displayed an appropriate expression
pro¢le (Fig. 4) ¢tting the biochemical ¢ndings. The mRNA
expression patterns obtained for two other peroxisomal mem-
brane proteins, PMP70 and PMP35, were almost identical to
the ACOX data (Berger et al., manuscript in preparation).
Interestingly, in rat at least two di¡erent long chain acyl-
CoA synthetases exist; the mRNA for the brain-enriched iso-
zyme is upregulated during brain development, while the liver-
enriched isozyme remains at a constant, low level in brain
during di¡erentiation [33]. Taken together, these data suggest
that additional isoforms of VLACS, with a di¡erent regula-
tory pattern, may exist in brain and possibly in other tissues.
Many VLACS-related sequences can be found in the EST
database and most of these were from kidney or liver-derived
cDNA libraries. Only a few were ampli¢ed from other tissues,
like diaphragm and embryonic heart, probably representing
mRNAs expressed at very low copy numbers. Other EST
clones display similar, but not identical cDNA sequences,
and may be candidates for other isoforms of VLACS. Future
analyses of such related sequences will show if some of these
represent transcripts of novel VLACS genes.
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